Join

Compare · GILD vs KLRS

GILD vs KLRS

Side-by-side comparison of Gilead Sciences Inc. (GILD) and Kalaris Therapeutics Inc. (KLRS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both GILD and KLRS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • GILD is the larger of the two at $161.88B, about 1155.5x KLRS ($140.1M).
  • Over the past year, GILD is up 22.6% and KLRS is down 8.4% - GILD leads by 31.0 points.
  • Both names hit the wire about 8 times in the past 4 weeks.
  • GILD has more recent analyst coverage (25 ratings vs 7 for KLRS).
PerformanceGILD+22.62%KLRS-8.36%
2025-04-28+0.00%2026-04-24
MetricGILDKLRS
Company
Gilead Sciences Inc.
Kalaris Therapeutics Inc.
Price
$130.38-2.48%
$6.14+0.90%
Market cap
$161.88B
$140.1M
1M return
-5.67%
+0.49%
1Y return
+22.62%
-8.36%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
1992
2020
News (4w)
8
8
Recent ratings
25
7
GILD

Gilead Sciences Inc.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.